In line with the previous results, the present study showed that both captopril and hydralazine, despite having different modes of action, reduce the circulating VCAM‐1 concentrations in SHR suggesting amelioration of the endothelial dysfunction with both anti‐hypertensive therapies. This evidence concerns the gene VCAM1 and endothelial dysfunction.